Candel Therapeutics Inc
CADL6.285USD
-0.005-0.08%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
309.52MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Candel Therapeutics Inc Unternehmen
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Unternehmensinformationen
BörsenkürzelCADL
Name des UnternehmensCandel Therapeutics Inc
IPO-datumJul 27, 2021
CEODr. Paul Peter Tak, M.D., Ph.D.
Anzahl der mitarbeiter38
WertpapierartOrdinary Share
GeschäftsjahresendeJul 27
Addresse117 Kendrick Street,
StadtNEEDHAM
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl02494
Telefon16179165445
Websitehttps://www.candeltx.com/
BörsenkürzelCADL
IPO-datumJul 27, 2021
CEODr. Paul Peter Tak, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
435.51K
--
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
+18.97%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
100.81K
+4.44%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
+14.07%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
38.03K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Edward J. Benz, Jr., M.D.
Dr. Edward J. Benz, Jr., M.D.
Independent Director
Independent Director
--
--
Ms. Seshu Tyagarajan, Ph.D.
Ms. Seshu Tyagarajan, Ph.D.
Chief Technical and Development Officer
Chief Technical and Development Officer
--
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. W. Garrett Nichols, M.D.
Dr. W. Garrett Nichols, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
435.51K
--
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
+18.97%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
100.81K
+4.44%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
+14.07%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
38.03K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
Umsatzaufteilung
FY2024
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 24
Aktualisiert: Sat, May 24
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
13.50%
Manning (Paul B.)
5.38%
Acorn Capital Advisors, LLC
4.92%
Baker Bros. Advisors LP
4.64%
Aguilar-Cordova (Estuardo)
4.61%
Other
66.94%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
13.50%
Manning (Paul B.)
5.38%
Acorn Capital Advisors, LLC
4.92%
Baker Bros. Advisors LP
4.64%
Aguilar-Cordova (Estuardo)
4.61%
Other
66.94%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
29.01%
Individual Investor
16.48%
Investment Advisor/Hedge Fund
6.21%
Hedge Fund
5.99%
Corporation
2.48%
Research Firm
0.64%
Bank and Trust
0.09%
Pension Fund
0.02%
Insurance Company
0.02%
Other
39.06%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
162
31.98M
60.95%
-104.17K
2025Q1
160
30.10M
67.51%
-1.81M
2024Q4
131
27.38M
62.24%
+9.09M
2024Q3
115
17.10M
48.26%
-703.44K
2024Q2
98
16.89M
49.23%
+872.97K
2024Q1
67
14.85M
50.59%
-1.40M
2023Q4
65
14.94M
51.56%
-1.48M
2023Q3
68
15.61M
53.96%
-846.00K
2023Q2
65
15.70M
54.30%
-590.47K
2023Q1
64
16.17M
55.93%
-250.07K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
7.09M
13.5%
+766.60K
+12.13%
Mar 31, 2025
Manning (Paul B.)
2.82M
5.38%
+500.00K
+21.52%
Apr 21, 2025
Acorn Capital Advisors, LLC
2.58M
4.92%
+428.26K
+19.90%
Jun 25, 2025
Baker Bros. Advisors LP
2.44M
4.64%
-544.79K
-18.27%
Mar 31, 2025
Aguilar-Cordova (Estuardo)
2.42M
4.61%
+190.92K
+8.57%
Apr 21, 2025
Aguilar (Laura K)
2.36M
4.49%
-690.05K
-22.65%
Apr 21, 2025
The Vanguard Group, Inc.
1.74M
3.31%
+396.95K
+29.64%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.61M
3.06%
+515.63K
+47.27%
Mar 31, 2025
BKB Growth Investments LLC
1.30M
2.48%
+750.00K
+135.44%
Apr 21, 2025
Portolan Capital Management, L.L.C.
881.18K
1.68%
+127.44K
+16.91%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
ALPS Medical Breakthroughs ETF
0.17%
Vanguard US Momentum Factor ETF
0.08%
iShares Micro-Cap ETF
0.05%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0%
Mehr Anzeigen
ALPS Medical Breakthroughs ETF
Anteil0.17%
Vanguard US Momentum Factor ETF
Anteil0.08%
iShares Micro-Cap ETF
Anteil0.05%
iShares Russell 2000 ETF
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0.01%
iShares Russell 2000 Growth ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
Global X Russell 2000 ETF
Anteil0.01%
ProShares Hedge Replication ETF
Anteil0.01%
iShares Russell 2000 Value ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
